A Phase 1 study of CBP-174 for the treatment of pruritus
Latest Information Update: 25 Aug 2020
Price :
$35 *
At a glance
- Drugs CBP-174 (Primary)
- Indications Pruritus
- Focus Adverse reactions
- Sponsors Suzhou Connect Biopharmaceuticals
- 25 Aug 2020 New trial record
- 24 Aug 2020 According to a Connect Biopharma media release, this study is expected to begin in the fourth quarter of 2020.